S-1: Acurx Pharmaceuticals Files for Resale of Up to 10.9 Million Shares of Common Stock

Acurx Pharmaceuticals has filed a registration statement for the resale of up to 10,899,258 shares of its common stock by Lincoln Park Capital Fund, LLC.

Summary

• Acurx Pharmaceuticals has filed a Form S-1 registration statement with the SEC to allow Lincoln Park Capital Fund, LLC to resell up to 10,899,258 shares of the company's common stock.
• These shares include 899,258 commitment shares already issued to Lincoln Park and up to 10,000,000 shares that may be issued to Lincoln Park under a purchase agreement.
• Acurx will not receive any proceeds from the resale of shares by Lincoln Park, but may receive up to $12.0 million in gross proceeds from the sale of shares to Lincoln Park under the purchase agreement.
• The company intends to use any proceeds received from the sale of shares to Lincoln Park for working capital and general corporate purposes.
• The last reported sale price of Acurx's common stock on Nasdaq on May 20, 2025, was $0.42 per share.
• The company is an emerging growth company and a smaller reporting company, which allows for reduced disclosure obligations.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company secures potential funding, the risk of dilution and market volatility tempers the positive aspects.

Positives

• The purchase agreement with Lincoln Park provides a potential source of funding for Acurx, up to $12.0 million.
• Acurx retains control over the timing and amount of any sales of common stock to Lincoln Park.
• The company's status as an emerging growth company and smaller reporting company allows for reduced disclosure obligations.
• The company intends to use net proceeds from such sales for working capital and general corporate purposes, which include, but are not limited to, research and development expenses and general and administrative expenses.

Negatives

• Sales of common stock to Lincoln Park could result in substantial dilution to existing stockholders.
• The market price of Acurx's common stock could decline due to sales of shares by Lincoln Park or the anticipation of such sales.
• Acurx may not have access to the full amount available under the purchase agreement with Lincoln Park.
• The company's management has broad discretion over the use of the net proceeds from sales of shares to Lincoln Park.

Risks

• The sale of common stock to Lincoln Park may cause dilution and the subsequent sale of the shares of common stock acquired by Lincoln Park, or the perception that such sales may occur, could cause the price of our common stock to fall.
• We may not have access to the full amount available under the Purchase Agreement with Lincoln Park.
• We may require additional financing to sustain our operations, without which we may not be able to continue operations, and the terms of subsequent financings may adversely impact our stockholders.
• Our management will have broad discretion over the use of the net proceeds, if any, from sales of shares of our common stock to Lincoln Park, you may not agree with how we use the proceeds and the proceeds may not be used effectively.

Future Outlook

The company intends to use the net proceeds from any sale of shares of common stock to Lincoln Park under the Purchase Agreement for working capital and general corporate purposes, which include, but are not limited to, research and development expenses and general and administrative expenses.

Industry Context

Acurx is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, which aligns with the global effort to combat antimicrobial resistance.

Comparison to Industry Standards

• It is difficult to compare Acurx directly to industry standards without knowing the specifics of their clinical trial results and market potential.
• However, similar companies in the biopharmaceutical space often trade based on the potential of their drug candidates and the size of the market they are targeting.
• Companies like Paratek Pharmaceuticals (PRTK) and Nabriva Therapeutics (NBRV) are developing antibiotics and have faced challenges in commercialization, highlighting the risks in this sector.

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of new shares to Lincoln Park.
• The company's employees and operations could benefit from the additional working capital provided by the purchase agreement.
• The company's ability to develop and commercialize its antibiotic candidates could be enhanced by the funding from Lincoln Park.

Next Steps

• The SEC must declare the registration statement effective before Acurx can commence sales of its common stock to Lincoln Park under the Purchase Agreement.
• Acurx may elect to sell shares to Lincoln Park at its discretion, subject to market conditions and other factors.
• Lincoln Park may resell the shares at any time or from time to time in its discretion.

Key Dates

Keywords

Acurx Pharmaceuticals, Lincoln Park Capital, common stock, resale, registration statement, financing, dilution, purchase agreement, ACXP